Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) EBT (2016 - 2025)

Historic EBT for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to -$35.1 million.

  • Sangamo Therapeutics' EBT fell 42612.45% to -$35.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$109.4 million, marking a year-over-year increase of 1891.04%. This contributed to the annual value of -$98.1 million for FY2024, which is 6268.28% up from last year.
  • As of Q3 2025, Sangamo Therapeutics' EBT stood at -$35.1 million, which was down 42612.45% from -$20.0 million recorded in Q2 2025.
  • Sangamo Therapeutics' EBT's 5-year high stood at $21.3 million during Q1 2023, with a 5-year trough of -$120.8 million in Q2 2023.
  • In the last 5 years, Sangamo Therapeutics' EBT had a median value of -$43.9 million in 2022 and averaged -$43.0 million.
  • Per our database at Business Quant, Sangamo Therapeutics' EBT tumbled by 364524.0% in 2021 and then surged by 14855.98% in 2023.
  • Sangamo Therapeutics' EBT (Quarter) stood at -$37.6 million in 2021, then plummeted by 37.67% to -$51.7 million in 2022, then fell by 17.12% to -$60.6 million in 2023, then soared by 60.67% to -$23.8 million in 2024, then plummeted by 47.3% to -$35.1 million in 2025.
  • Its last three reported values are -$35.1 million in Q3 2025, -$20.0 million for Q2 2025, and -$30.5 million during Q1 2025.